The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach
Open accessAbstract
The U.S. Food and Drug Administration (FDA) has recently issued an Emergency Use Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. This has brought hope to millions of Americans in the midst of an ongoing global pandemic. The FDA EUA guidance for both vaccines is to not administer the vaccine to individuals with a known history of a severe allergic reaction (eg, anaphylaxis) to any component of the COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) additionally advises individuals with a history of an immediate allergic reaction to a vaccine or injectable or any history of anaphylaxis be observed for 30 minutes after COVID-19 vaccination. All other individuals should be observed for 15 minutes after COVID-19 vaccination. Staff at vaccine clinics must be able to identify and manage anaphylaxis. Post–FDA EUA, despite very strong safety signals in both phase 3 trials, reports of possible allergic reactions have raised public concern. To provide reassurance and support during widespread global vaccination, allergists must offer clear guidance to individuals based on the best information available, but also in accordance with the broader recommendations of regulatory agencies. This review summarizes vaccine allergy epidemiology and proposes drug and vaccine allergy expert opinion informed risk stratification for Allergy specialist use in conjunction with guidance of public health and regulatory authorities. The risk stratification schema guide care for (1) individuals with different allergy histories to safely receive their first mRNA COVID-19 vaccine and (2) individuals who develop a reaction to their first dose of mRNA COVID-19 vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationShaker, M. S., Wallace, D. V., Golden, D. B. K., Oppenheimer, J., Bernstein, J. A., Campbell, R. L., Dinakar, C., Ellis, A., Greenhawt, M., Khan, D. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.017 · Cited by 715
Self-citationAnti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7002e1 · Cited by 479
Risk of anaphylaxis after vaccination in children and adults.
McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.048 · Cited by 381
Immediate‐type hypersensitivity to polyethylene glycols: a review
Wenande, E., & Garvey, L. H. (2016) · Clinical & Experimental Allergy · doi:10.1111/cea.12760 · Cited by 354
Stone, C. A., Liu, Y., Relling, M. V., Krantz, M. S., Pratt, A. L., Abreo, A., Hemler, J. A., & Phillips, E. J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.12.003 · Cited by 351
Self-citationAdverse reactions to vaccines practice parameter 2012 update
Kelso, J. M., Greenhawt, M. J., Li, J. T., Nicklas, R. A., Bernstein, D. I., Blessing-Moore, J., Cox, L., Khan, D., Lang, D. M., Oppenheimer, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.003 · Cited by 293
Self-citationPolysorbate 80 in medical products and nonimmunologic anaphylactoid reactions
Coors, E. A., Seybold, H., Merk, H. F., & Mahler, V. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61024-1 · Cited by 238
Cited by
Pollock, K. M., Cheeseman, H. M., Szubert, A. J., Libri, V., Boffito, M., Owen, D., Bern, H., McFarlane, L. R., O'Hara, J., Lemm, N.-M., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101262 · Cited by 173
Metadata
- Authors
- Banerji, A., Wickner, P. G., Saff, R., Stone, C. A., Robinson, L. B., Long, A. A., Wolfson, A. R., Williams, P., Khan, D. A., Phillips, E., & Blumenthal, K. G.
- Venue
- The Journal of Allergy and Clinical Immunology: In Practice
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 9
- Issue
- 4
- Pages
- 1423-1437
- ISSN
- 2213-2198 (ISSN-L)
- OpenAlex
- W3114586947
- Cited by
- 452
- References
- 27
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. https://app.cochat.ai/papers/10.1016/j.jaip.2020.12.047
- The paper
- Banerji, A., Wickner, P. G., Saff, R., Stone, C. A., Robinson, L. B., Long, A. A., Wolfson, A. R., Williams, P., Khan, D. A., Phillips, E., & Blumenthal, K. G. (2021). mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2020.12.047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
